

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1617SXX

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	DEC 01	ChemPort single article sales feature unavailable
NEWS	3	APR 03	CAS coverage of exemplified prophetic substances enhanced
NEWS	4	APR 07	STN is raising the limits on saved answers
NEWS	5	APR 24	CA/CAPLUS now has more comprehensive patent assignee information
NEWS	6	APR 26	USPATFULL and USPAT2 enhanced with patent assignment/reassignment information
NEWS	7	APR 28	CAS patent authority coverage expanded
NEWS	8	APR 28	ENCOMPLIT/ENCOMPLIT2 search fields enhanced
NEWS	9	APR 28	Limits doubled for structure searching in CAS REGISTRY
NEWS	10	MAY 08	STN Express, Version 8.4, now available
NEWS	11	MAY 11	STN on the Web enhanced
NEWS	12	MAY 11	BEILSTEIN substance information now available on STN Easy
NEWS	13	MAY 14	DGENE, PCTGEN and USGENE enhanced with increased limits for exact sequence match searches and introduction of free HIT display format
NEWS	14	MAY 15	INPADOCDB and INPAFAMDB enhanced with Chinese legal status data
NEWS	15	MAY 28	CAS databases on STN enhanced with NANO super role in records back to 1992
NEWS	16	JUN 01	CAS REGISTRY Source of Registration (SR) searching enhanced on STN

NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 11:56:56 ON 12 JUN 2009

```
=> file reg
COST IN U.S. DOLLARS          SINCE FILE      TOTAL
                               ENTRY      SESSION
FULL ESTIMATED COST          0.22      0.22
```

FILE 'REGISTRY' ENTERED AT 11:57:20 ON 12 JUN 2009
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 10 JUN 2009 HIGHEST RN 1155458-91-5
 DICTIONARY FILE UPDATES: 10 JUN 2009 HIGHEST RN 1155458-91-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
 predicted properties as well as tags indicating availability of
 experimental property data in the original document. For information
 on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>


```
=> s efavirenz
L1          3 EFAVIRENZ

=> s efavirenz/cn
L2          1 EFAVIRENZ/CN

=> d L2 str cn rn
```

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2009 ACS on STN

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

CN 2H-3,1-Benzoxazin-2-one, 6-chloro-4-(2-cyclopropylethynyl)-1,4-dihydro-4-
 (trifluoromethyl)-, (4S)- (CA INDEX NAME)
 OTHER CA INDEX NAMES:

CN 2H-3,1-Benzoxazin-2-one, 6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-, (4S)- (9CI)
 CN 2H-3,1-Benzoxazin-2-one, 6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-, (S)-
 OTHER NAMES:
 CN (-)-Efavirenz
 CN DMP 266
 CN Efavirenz
 CN L 743726
 CN Stocrin
 CN Sustiva
 RN 154598-52-4 REGISTRY

=> file caplus medline biosis embase

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	13.71	13.93

FILE 'CAPLUS' ENTERED AT 11:58:24 ON 12 JUN 2009
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 11:58:24 ON 12 JUN 2009

FILE 'BIOSIS' ENTERED AT 11:58:24 ON 12 JUN 2009
 Copyright (c) 2009 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 11:58:24 ON 12 JUN 2009
 Copyright (c) 2009 Elsevier B.V. All rights reserved.

=> s efavirenz

L3 12664 EFAVIRENZ

=> s 154598-52-4

L4 10554 154598-52-4

=> s L3 or L4

L5 12776 L3 OR L4

=> dup rem L5

PROCESSING IS APPROXIMATELY 14% COMPLETE FOR L5
 PROCESSING IS APPROXIMATELY 22% COMPLETE FOR L5
 PROCESSING IS APPROXIMATELY 25% COMPLETE FOR L5
 PROCESSING IS APPROXIMATELY 28% COMPLETE FOR L5
 PROCESSING IS APPROXIMATELY 36% COMPLETE FOR L5
 PROCESSING IS APPROXIMATELY 42% COMPLETE FOR L5
 PROCESSING IS APPROXIMATELY 49% COMPLETE FOR L5
 PROCESSING IS APPROXIMATELY 56% COMPLETE FOR L5
 PROCESSING IS APPROXIMATELY 63% COMPLETE FOR L5
 PROCESSING IS APPROXIMATELY 70% COMPLETE FOR L5
 PROCESSING IS APPROXIMATELY 77% COMPLETE FOR L5
 PROCESSING IS APPROXIMATELY 83% COMPLETE FOR L5
 PROCESSING IS APPROXIMATELY 90% COMPLETE FOR L5
 PROCESSING IS APPROXIMATELY 98% COMPLETE FOR L5
 PROCESSING COMPLETED FOR L5
 L6 9187 DUP REM L5 (3589 DUPLICATES REMOVED)

=> s tumor or cancer or neoplasm

L7 6196235 TUMOR OR CANCER OR NEOPLASM

=> s L6 and L7
L8 508 L6 AND L7

=> s L8 and (AY<2003 or PY<2003 or PRY<2003)
'2003' NOT A VALID FIELD CODE
'2003' NOT A VALID FIELD CODE
'2003' NOT A VALID FIELD CODE
'2003' NOT A VALID FIELD CODE
'2003' NOT A VALID FIELD CODE
'2003' NOT A VALID FIELD CODE
L9 102 L8 AND (AY<2003 OR PY<2003 OR PRY<2003)

=> s cell proliferation
L10 591342 CELL PROLIFERATION

=> s L9 and L10
L11 3 L9 AND L10

=> d L11 1-3 ibib abs

L11 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:238670 CAPLUS
DOCUMENT NUMBER: 142:303644
TITLE: Compositions comprising
phosphatidylethanolamine-binding peptides linked to
anti-viral agents
INVENTOR(S): Thorpe, Philip E.; Soares, M. Melina; He, Jin
PATENT ASSIGNEE(S): Board of Regents, The University of Texas System, USA
SOURCE: U.S. Pat. Appl. Publ., 182 pp., Cont.-in-part of U.S.
Ser. No. 621,269.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 17
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050059578	A1	20050317	US 2003-642121	20030815 <--
US 7511124	B2	20090331		
US 20040170620	A1	20040902	US 2003-621269	20030715 <--
PRIORITY APPLN. INFO.:			US 2002-396263P	P 20020715 <--
			US 2003-621269	A2 20030715

AB Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compns. and methods for utilizing these findings in the treatment of cancer and viral infections. Also disclosed are advantageous antibody, immunoconjugate and duramycin-based compns. and combinations that bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases. The pharmaceutical compns. and treatment methods of the invention employ "therapeutically effective amts." of an anti-aminophospholipid or anti-anionic phospholipid antibody, optionally one that binds to substantially the same epitope as the monoclonal antibody 9D2 or 3G4, or an antigen binding fragment or immunoconjugate of such an antibody, or a substantially cell impermeant PE-binding peptide derivative, preferably a substantially cell impermeant duramycin derivative, or an anti-viral conjugate thereof.

REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:41226 CAPLUS
 DOCUMENT NUMBER: 140:105321
 TITLE: Methods and compositions relating to isoleucine boroproline compounds
 INVENTOR(S): Adams, Sharlene; Miller, Glenn T.; Jesson, Michael I.; Jones, Barry
 PATENT ASSIGNEE(S): Point Therapeutics, Inc., USA
 SOURCE: PCT Int. Appl., 152 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004004658	A2	20040115	WO 2003-US21405	20030709 <--
WO 2004004658	A3	20050804		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2491466	A1	20040115	CA 2003-2491466	20030709 <--
AU 2003265264	A1	20040123	AU 2003-265264	20030709 <--
US 20040077601	A1	20040422	US 2003-616694	20030709 <--
US 20050084490	A1	20050421	US 2003-616409	20030709 <--
EP 1578434	A2	20050928	EP 2003-763380	20030709 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006507352	T	20060302	JP 2004-562634	20030709 <--
CN 1802090	A	20060712	CN 2003-821282	20030709 <--
CN 1826129	A	20060830	CN 2003-821281	20030709 <--
IN 2005KN00151	A	20050916	IN 2005-KN151	20050208 <--
PRIORITY APPLN. INFO.:			US 2002-394856P	P 20020709 <--
			US 2002-414978P	P 20021001 <--
			US 2003-466435P	P 20030428
			WO 2003-US21405	W 20030709

OTHER SOURCE(S): MARPAT 140:105321

AB A method for treating subjects with, inter alia, abnormal cell proliferation or infectious disease using agents of formula (I, AmNHCH(CH(CH3)CH2CH3)COAlR) (where Am and Al are amino acids and R = organo boronates, organo phosphonates, fluoroalkyl ketones, alphaketos, N-peptidyl-O-(acylhydroxylamines), azapeptides, azetidines, fluoroolefins dipeptide isosteres, peptidyl (α -aminoalkyl) phosphonate esters, aminoacyl pyrrolidine-2-nitriles and 4-cyanothiazolidides) is claimed. Methods for stimulating an immune response using the compds. of the invention are also claimed. Compns. containing Ile-boroPro compds. are also provided as are kits containing the compns. The invention embraces the use of these compds. alone or in combination with other therapeutic agents.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:532527 CAPLUS
 DOCUMENT NUMBER: 139:79132
 TITLE: Non-nucleosidic inhibitors of reverse transcriptase as

antagonists of cell proliferation
and inducers of cell differentiation

INVENTOR(S): Spadafora, Corrado; Lavia, Patrizia; Mattei,
Elisabetta; Palombini, Guglielmo; Lorenzini, Rodolfo
Nello; Granito, Alfredo; Nervi, Clara

PATENT ASSIGNEE(S): Italy

SOURCE: PCT Int. Appl., 41 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003055493	A1	20030710	WO 2002-EP14727	20021223 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
IT 2001RM0767	A1	20030624	IT 2001-RM767	20011224 <--
CA 2471543	A1	20030710	CA 2002-2471543	20021223 <--
AU 2002358793	A1	20030715	AU 2002-358793	20021223 <--
AU 2002358793	B2	20080424		
EP 1469858	A1	20041027	EP 2002-793112	20021223 <--
EP 1469858	B1	20080709		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
CN 1607953	A	20050420	CN 2002-826053	20021223 <--
CN 100450487	C	20090114		
JP 2005513147	T	20050512	JP 2003-556070	20021223 <--
HU 2006000841	A2	20070502	HU 2006-841	20021223 <--
NZ 534257	A	20080328	NZ 2002-534257	20021223 <--
AT 400276	T	20080715	AT 2002-793112	20021223 <--
ES 2309222	T3	20081216	ES 2002-793112	20021223 <--
MX 2004006205	A	20050725	MX 2004-6205	20040622 <--
US 20060166970	A1	20060727	US 2005-500270	20050725 <--

PRIORITY APPLN. INFO.:

IT 2001-RM767	A	20011224 <--
IT 2002-MI1833	A	20020819 <--
WO 2002-EP14727	W	20021223 <--

AB The invention refers to the use of Reverse Transcriptase (RT) inhibitor compds. for the preparation of pharmaceutical compns. to counteract the loss of cellular differentiation in tumor and non tumor pathologies, said compound being able to bind the hydrophobic pocket on the RT subunit p66. Particularly preferred for such uses are the following compds.: nevirapine, efavirenz, delavirdine, corresponding salts and/or pharmaceutically acceptable derivs. thereof. Growth of Morris 3924A rat hepatomas were inhibited in rats by treatment with nevirapine or efavirenz.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d L9 90-102 ibib abs

reserved on STN

ACCESSION NUMBER: 2001197270 EMBASE
TITLE: 38th Annual Meeting of the SENFC (Spanish Society of Clinical Neurophysiology), Barcelona, Spain, December 14-16, 2000.
AUTHOR: Ferrandiz, M. (correspondence)
CORPORATE SOURCE: Hospital Universitario Josep Trueta, Neurofisiologia Clinica, Avda Franca, s/n, 17007 Gerona, Spain.
SOURCE: Clinical Neurophysiology, (2001) Vol. 112, No. 6, pp. 1128-1138.
ISSN: 1388-2457 CODEN: CNEUFU
PUBLISHER IDENT.: S 1388-2457(01)00539-9
COUNTRY: Ireland
DOCUMENT TYPE: Journal; Conference Article; (Conference paper)
FILE SEGMENT: 027 Biophysics, Bioengineering and Medical Instrumentation
037 Drug Literature Index
038 Adverse Reactions Titles
050 Epilepsy Abstracts
008 Neurology and Neurosurgery
LANGUAGE: English
ENTRY DATE: Entered STN: 14 Jun 2001
Last Updated on STN: 14 Jun 2001

L9 ANSWER 91 OF 102 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2001164586 EMBASE
TITLE: HIV dementia complex - A review.
AUTHOR: Mujic, F.; Everall, I.P. (correspondence)
CORPORATE SOURCE: Department of Neuropathology, Institute of Psychiatry, DeCrespigny Park, London SE5 8AF, United Kingdom.
i.everall@iop.bpmf.ac.uk
SOURCE: Italian Journal of Psychiatry and Behavioural Sciences, (1999) Vol. 9, No. 2, pp. 31-35.
Refs: 56
ISSN: 1122-2247 CODEN: IPBSFL
COUNTRY: Italy
DOCUMENT TYPE: Journal; General Review; (Review)
FILE SEGMENT: 030 Clinical and Experimental Pharmacology
037 Drug Literature Index
004 Microbiology: Bacteriology, Mycology, Parasitology and Virology
005 General Pathology and Pathological Anatomy
008 Neurology and Neurosurgery
LANGUAGE: English
ENTRY DATE: Entered STN: 17 May 2001
Last Updated on STN: 17 May 2001

L9 ANSWER 92 OF 102 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2001084050 EMBASE
TITLE: Public health service task force recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States.
SOURCE: HIV Clinical Trials, (2001) Vol. 2, No. 1, pp. 56-91.
Refs: 144
ISSN: 1528-4336 CODEN: HCTIA8
COUNTRY: United States
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 010 Obstetrics and Gynecology
017 Public Health, Social Medicine and Epidemiology

037 Drug Literature Index
038 Adverse Reactions Titles
004 Microbiology: Bacteriology, Mycology, Parasitology
and Virology
007 Pediatrics and Pediatric Surgery

LANGUAGE: English

SUMMARY LANGUAGE: English

ENTRY DATE: Entered STN: 16 Mar 2001

Last Updated on STN: 16 Mar 2001

AB These recommendations update the February 15: 2000 guidelines developed by the Public Health Service for the use of zidovudine (ZDV) to reduce the risk for perinatal human immunodeficiency virus type 1 (HIV-1) transmission.* This report provides health-care providers with information for discussion with HIV-1 infected pregnant women to enable such women to make an informed decision regarding the use of antiretroviral drugs during pregnancy and use of elective cesarean delivery to reduce perinatal HIV-1 transmission. Various circumstances that commonly occur in clinical practice are presented as scenarios and the factors influencing treatment considerations are highlighted in this report. It is recognized that strategies to prevent perinatal transmission and concepts related to management of HIV disease in pregnant women ,are rapidly evolving. The Prerinatal HIV Guidelines Working Group will review new data on an ongoing basis and provide regular updates to the guidelines; the most recent information is available on the HIV/such exposure should be part of the ongoing medical record of the child--particularly for uninfected children. Follow-up of children with antiretroviral exposure should continue into adulthood because of the theoretical concerns regarding potential for carcinogenicity of the nucleoside analogue antiretroviral drugs. Long-term follow-up should include yearly physical examination of all children exposed to antiretrovirals and for older adolescent females, gynecologic evaluation with pap smears. On a population basis, HIV-1 surveillance databases from states that require HIV-1 reporting provide an opportunity to collect information concerning in utero antiretroviral exposure. To the extent permitted by federal law and regulations, data from these confidential registries can be used to compare with information from birth defect and cancer registries to identify potential adverse outcomes.

L9 ANSWER 93 OF 102 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2001077655 EMBASE

TITLE: HIV-1-associated cognitive-motor disorders: A research-based approach to diagnosis and treatment.

AUTHOR: Goodkin, K., Dr. (correspondence); Wilkie, F.L.; Baldewicz, T.T.; Concha, M.; Tyll, M.D.; LoPiccolo, C.J.; Shapshak, P.

CORPORATE SOURCE: Dept. of Psychiat./Behavioral Sci., University of Miami, School of Medicine, Miami, FL, United States.

SOURCE: CNS Spectrums, (2000) Vol. 5, No. 8, pp. 49-60.

Refs: 77

ISSN: 1092-8529 CODEN: CNSPFH

COUNTRY: United States

DOCUMENT TYPE: Journal; Article

FILE SEGMENT: 037 Drug Literature Index

004 Microbiology: Bacteriology, Mycology, Parasitology
and Virology

005 General Pathology and Pathological Anatomy

008 Neurology and Neurosurgery

LANGUAGE: English

SUMMARY LANGUAGE: English

ENTRY DATE: Entered STN: 8 Mar 2001

Last Updated on STN: 8 Mar 2001

AB The diagnosis of human immunodeficiency virus type 1 (HIV-1) - associated

cognitive-motor disorder - either minor cognitive-motor disorder (MCMD) or HIV-1 - associated dementia (HAD) - is fraught with potential pitfalls for the clinician. Before making such a diagnosis, clinicians should exclude other etiologies by using neuroimaging, lumbar puncture, and serum chemistries to screen for opportunistic and non-opportunistic infections of the brain and meninges. Clinicians should also consider psychoneurotoxicity (caused from the use of psychoactive substances and prescribed medications) and psychopathology, such as mood, anxiety, and other disorders. In addition, a thorough medical history and physical examination, including a complete neurologic and neuropsychiatric mental status examination, are necessary for an accurate diagnosis. There is also a need for standardized neuropsychological and functional status tests, since the diagnostic criteria for these disorders are partly based on these criteria. Treatment targets should include subclinical cognitive-motor impairment and neuroprotection, as well as MCMD and HAD. Currently, zidovudine remains the best proven treatment for these disorders, but other nucleoside reverse transcriptase inhibitors, as well as nonnucleoside reverse transcriptase inhibitors and protease inhibitors, show promise, and selected agents from these classes are being tested in clinical trials. Other areas that should be investigated are the modulation of inflammatory mediators (such as tumor necrosis factor α), neurotransmitter manipulation (especially of dopamine), and nutritional interventions.

L9 ANSWER 94 OF 102 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2000376000 EMBASE
 TITLE: Highly active antiretroviral therapy does not protect against Kaposi's sarcoma in HIV-infected individuals [6].
 AUTHOR: Zala, C. (correspondence); Ochoa, C.; Krolewiecki, A.; Patterson, P.; Cahn, P.; Crawford, R.I.; Montaner, J.S.G.
 CORPORATE SOURCE: Fundacion Huesped, Buenos Aires, Argentina.
 SOURCE: AIDS, (2000) Vol. 14, No. 14, pp. 2217-2218.
 Refs: 13
 ISSN: 0269-9370 CODEN: AIDSET
 COUNTRY: United Kingdom
 DOCUMENT TYPE: Journal; Letter
 FILE SEGMENT: 016 Cancer
 037 Drug Literature Index
 004 Microbiology: Bacteriology, Mycology, Parasitology and Virology
 LANGUAGE: English
 ENTRY DATE: Entered STN: 16 Nov 2000
 Last Updated on STN: 16 Nov 2000

L9 ANSWER 95 OF 102 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2000236334 EMBASE
 TITLE: Cerebrospinal fluid Epstein-Barr virus detection preceding HIV-associated primary central nervous system lymphoma by 17 months.
 AUTHOR: Al-Shahi, R. (correspondence); Bower, M.; Nelson, M.R.; Gazzard, B.G.
 CORPORATE SOURCE: Department of Clinical Neurosciences, Western General Hospital, Crewe Road, Edinburgh EH4 2XU, United Kingdom. ras@skull.dcn.ed.ac.uk
 SOURCE: Journal of Neurology, (2000) Vol. 247, No. 6, pp. 471-472.
 Refs: 7
 ISSN: 0340-5354 CODEN: JNRYA9
 COUNTRY: Germany
 DOCUMENT TYPE: Journal; Article
 FILE SEGMENT: 016 Cancer

025 Hematology
037 Drug Literature Index
004 Microbiology: Bacteriology, Mycology, Parasitology
and Virology
008 Neurology and Neurosurgery
LANGUAGE: English
ENTRY DATE: Entered STN: 20 Jul 2000
Last Updated on STN: 20 Jul 2000

L9 ANSWER 96 OF 102 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2000155111 EMBASE
TITLE: Drug interactions with drugs used in the treatment of HIV and infective complications peculiar to HIV infected patients.
AUTHOR: Griffin, J.P., Dr. (correspondence)
CORPORATE SOURCE: Quartermans, Digswell Lane, Digswell, Herts. AL7 1SP, United Kingdom.
SOURCE: Adverse Drug Reactions and Toxicological Reviews, (Mar 2000) Vol. 19, No. 1, pp. 47-88.
Refs: 20
ISSN: 0964-198X CODEN: ADRRER
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; General Review; (Review)
FILE SEGMENT: 037 Drug Literature Index
038 Adverse Reactions Titles
004 Microbiology: Bacteriology, Mycology, Parasitology and Virology
LANGUAGE: English
ENTRY DATE: Entered STN: 18 May 2000
Last Updated on STN: 18 May 2000

L9 ANSWER 97 OF 102 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2000137200 EMBASE
TITLE: From antivirals to hair loss: Drug review of 1999.
AUTHOR: Hopkins, S.
SOURCE: Manufacturing Chemist, (2000) Vol. 71, No. 4, pp. 12-14.
Refs: 0
ISSN: 0262-4230 CODEN: MCHMDI
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; Note
FILE SEGMENT: 030 Clinical and Experimental Pharmacology
037 Drug Literature Index
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 4 May 2000
Last Updated on STN: 4 May 2000

AB The past year has seen a plethora of compounds come onto market to treat a myriad of conditions, and they are reviewed here.

L9 ANSWER 98 OF 102 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2000109102 EMBASE
TITLE: High-dose therapy and autologous haematopoietic stem-cell transplantation for HIV-1-associated lymphoma.
AUTHOR: Gabarre, Jean, Dr. (correspondence); Azar, Nabih; Leblond, Veronique
CORPORATE SOURCE: Services of Clinical Haematology, Hop. Pitie-Salpetriere, Paris, France. jean.gabarre@psl.ap-hop-paris.fr
AUTHOR: Katlama, Christine
CORPORATE SOURCE: Services of Infectious Diseases, Hop. Pitie-Salpetriere,

Paris, France.
AUTHOR: Autran, Brigitte
CORPORATE SOURCE: Department of Cellular Immunology, Hop. Pitie-Salpetriere,
Paris, France.
AUTHOR: Gabarre, Jean, Dr. (correspondence)
CORPORATE SOURCE: Service d'Hematologie Clinique, Hopital Pitie-Salpetriere,
47 Boulevard de l'Hopital, 75651 Paris, France. jean.gabarr
e@psl.ap-hop-paris.fr
SOURCE: Lancet, (25 Mar 2000) Vol. 355, No. 9209, pp. 1071-1072.
Refs: 3
ISSN: 0140-6736 CODEN: LANCAO
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 016 Cancer
026 Immunology, Serology and Transplantation
037 Drug Literature Index
004 Microbiology: Bacteriology, Mycology, Parasitology
and Virology
006 Internal Medicine
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 6 Apr 2000
Last Updated on STN: 6 Apr 2000

AB We describe the results of autologous haematopoietic stem-cell
transplantation in eight patients with HIV-1-associated lymphoma.
Collection and grafting of stem cells is feasible and this treatment seems
appropriate in chemotherapy-sensitive HIV-1-associated lymphoma.

L9 ANSWER 99 OF 102 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights
reserved on STN

ACCESSION NUMBER: 2000078346 EMBASE
TITLE: US drug and biologic approvals in 1998.
AUTHOR: Spilker, B.; FitzSimmons, S., Dr. (correspondence); Horan,
M.
CORPORATE SOURCE: 1100 15(th) Street NW, Washington, DC 20005, United States.
sfitzsim@phrma.org
SOURCE: Drug Development Research, (1999) Vol. 48, No. 4, pp.
139-153.
ISSN: 0272-4391 CODEN: DDREDK
COUNTRY: United States
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 036 Health Policy, Economics and Management
037 Drug Literature Index
039 Pharmacy
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 9 Mar 2000
Last Updated on STN: 9 Mar 2000

AB The Prescription Drug User Fee Act of 1992 enhanced review resources for
the Food and Drug Administration (FDA). The past 3 years have seen an
unprecedented approval of 122 new drugs and 28 new biologics. Information
is provided on the 39 new products approved by the FDA in 1998. (C) 1999
Wiley- Liss, Inc.

L9 ANSWER 100 OF 102 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights
reserved on STN

ACCESSION NUMBER: 2000045053 EMBASE
TITLE: New drug update: Etanercept and amprenavir.
AUTHOR: Hussar, D.A., Dr. (correspondence)
CORPORATE SOURCE: Philadelphia College of Pharmacy, Univ. of Sciences in
Philadelphia, Philadelphia, PA, United States.
SOURCE: American Druggist, (1999) Vol. 216, No. 12, pp. 52-55.

ISSN: 0190-5279 CODEN: AMDRAG
COUNTRY: United States
DOCUMENT TYPE: Journal; General Review; (Review)
FILE SEGMENT: 030 Clinical and Experimental Pharmacology
031 Arthritis and Rheumatism
037 Drug Literature Index
038 Adverse Reactions Titles
004 Microbiology: Bacteriology, Mycology, Parasitology
and Virology
LANGUAGE: English
ENTRY DATE: Entered STN: 10 Feb 2000
Last Updated on STN: 10 Feb 2000

L9 ANSWER 101 OF 102 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2000014482 EMBASE
TITLE: [New drugs in 1999].
Neue arzneimittel 1999.
AUTHOR: Hellwig, B.
SOURCE: Deutsche Apotheker Zeitung, (23 Dec 1999) Vol. 139, No. 51-52 SUPPL., pp. 9-16.
ISSN: 0011-9857 CODEN: DAZE2
COUNTRY: Germany
DOCUMENT TYPE: Journal; (Short Survey)
FILE SEGMENT: 030 Clinical and Experimental Pharmacology
037 Drug Literature Index
LANGUAGE: German
ENTRY DATE: Entered STN: 20 Jan 2000
Last Updated on STN: 20 Jan 2000

L9 ANSWER 102 OF 102 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 1996367259 EMBASE
TITLE: Current Antiviral Agents FactFile. 2nd Edition: Part II - Human immunodeficiency viruses.
AUTHOR: Kinchington, D.; Minshull, C.; Drummond, C.
SOURCE: International Antiviral News, (1996) Vol. 4, No. 7, pp. 132-144.
ISSN: 0965-2310 CODEN: IANWEL
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; General Review; (Review)
FILE SEGMENT: 030 Clinical and Experimental Pharmacology
037 Drug Literature Index
004 Microbiology: Bacteriology, Mycology, Parasitology
and Virology
LANGUAGE: English
ENTRY DATE: Entered STN: 9 Jan 1997
Last Updated on STN: 9 Jan 1997

=> s L9 NOT HIV
L12 30 L9 NOT HIV

=> d L12 1-10 ibib abs

L12 ANSWER 1 OF 30 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:238670 CAPLUS
DOCUMENT NUMBER: 142:303644
TITLE: Compositions comprising
phosphatidylethanolamine-binding peptides linked to
anti-viral agents
INVENTOR(S): Thorpe, Philip E.; Soares, M. Melina; He, Jin

PATENT ASSIGNEE(S): Board of Regents, The University of Texas System, USA
SOURCE: U.S. Pat. Appl. Publ., 182 pp., Cont.-in-part of U.S.
Ser. No. 621,269.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 17
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050059578	A1	20050317	US 2003-642121	20030815 <--
US 7511124	B2	20090331		
US 20040170620	A1	20040902	US 2003-621269	20030715 <--
PRIORITY APPLN. INFO.:			US 2002-396263P	P 20020715 <--
			US 2003-621269	A2 20030715

AB Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compns. and methods for utilizing these findings in the treatment of cancer and viral infections. Also disclosed are advantageous antibody, immunoconjugate and duramycin-based compns. and combinations that bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases. The pharmaceutical compns. and treatment methods of the invention employ "therapeutically effective amts." of an anti-aminophospholipid or anti-anionic phospholipid antibody, optionally one that binds to substantially the same epitope as the monoclonal antibody 9D2 or 3G4, or an antigen binding fragment or immunoconjugate of such an antibody, or a substantially cell impermeant PE-binding peptide derivative, preferably a substantially cell impermeant duramycin derivative, or an anti-viral conjugate thereof.

REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 2 OF 30 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:905598 CAPLUS
DOCUMENT NUMBER: 141:374693
TITLE: Anti-viral treatment methods using
phosphatidylethanolamine-binding peptide derivatives
INVENTOR(S): Thorpe, Philip E.; Soares, M. Melina; He, Jin
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 181 pp., Cont.-in-part of U.S.
Ser. No. 621,269.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 17
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040214764	A1	20041028	US 2003-642117	20030815 <--
US 7378386	B2	20080527		
US 20040170620	A1	20040902	US 2003-621269	20030715 <--
PRIORITY APPLN. INFO.:			US 2002-396263P	P 20020715 <--
			US 2003-621269	A2 20030715

AB Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compns. and methods for utilizing these findings in the treatment of cancer and viral infections. Also disclosed are advantageous antibody, immunoconjugate and duramycin-based compns. and combinations that bind and inhibit anionic phospholipids and

aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases.

REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 3 OF 30 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:905361 CAPLUS

DOCUMENT NUMBER: 141:388642

TITLE: Methods for treating tumors and viral infections by using antibodies, immunoconjugates and duramycin-based compounds to inhibit anionic phospholipids and aminophospholipids

INVENTOR(S): Thorpe, Philip E.; Soares, M. Melina; Ran, Sophia

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 181 pp., Cont.-in-part of U.S. Ser. No. 621,269.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 17

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040213779	A1	20041028	US 2003-642119	20030815 <--
US 20040170620	A1	20040902	US 2003-621269	20030715 <--
PRIORITY APPLN. INFO.:			US 2002-396263P	P 20020715 <--
			US 2003-621269	A2 20030715

AB Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compns. and methods for utilizing these findings in the treatment of cancer and viral infections. Also disclosed are advantageous antibody, immunoconjugate and duramycin-based compns. and combinations that bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases.

L12 ANSWER 4 OF 30 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:550532 CAPLUS

DOCUMENT NUMBER: 141:105254

TITLE: Humanized or chimeric antibodies specific to aminophospholipid and immunoconjugates with antiviral or antitumor agent for treating viral infection and cancer

INVENTOR(S): Thorpe, Philip E.; Soares, M. Melina; Ran, Sophia

PATENT ASSIGNEE(S): Board of Regents, University of Texas System, USA

SOURCE: U.S. Pat. Appl. Publ., 182 pp., Cont.-in-part of U.S. Ser. No. 621,269.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 17

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040131622	A1	20040708	US 2003-642122	20030815 <--
US 20040170620	A1	20040902	US 2003-621269	20030715 <--
PRIORITY APPLN. INFO.:			US 2002-396263P	P 20020715 <--
			US 2003-621269	A2 20030715

AB Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in

viral entry and spread, and compns. and methods for utilizing these findings in the treatment of cancer and viral infections. Also disclosed are advantageous antibody, immunoconjugate and duramycin-based compns. and combinations that bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases.

L12 ANSWER 5 OF 30 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:550531 CAPLUS
DOCUMENT NUMBER: 141:105253
TITLE: Antibodies specific to aminophospholipid and conjugates for diagnosis and treatment of cancer and viral infection
INVENTOR(S): Thorpe, Philip E.; Soares, M. Melina; Ran, Sophia
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 178 pp., Cont.-in-part of U.S. Ser. No. 621,269.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 17
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040131621	A1	20040708	US 2003-642060	20030815 <--
US 20040170620	A1	20040902	US 2003-621269	20030715 <--
PRIORITY APPLN. INFO.:			US 2002-396263P	P 20020715 <--
			US 2003-621269	A2 20030715

AB Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compns. and methods for utilizing these findings in the treatment of cancer and viral infections. Also disclosed are advantageous antibody, immunoconjugate and duramycin-based compns. and combinations that bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases.

L12 ANSWER 6 OF 30 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:60253 CAPLUS
DOCUMENT NUMBER: 140:127195
TITLE: Antibodies specifically bind to anionic phospholipids and/or aminophospholipids conjugated with duramycin peptide for treating viral infections and cancer
INVENTOR(S): Thorpe, Philip E.; Soares, Melina M.; Huang, Xianming; He, Jin; Ran, Sophia
PATENT ASSIGNEE(S): Board of Regents the University of Texas System, USA
SOURCE: PCT Int. Appl., 378 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 17
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004006847	A2	20040122	WO 2003-US21925	20030715 <--
WO 2004006847	A3	20050407		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,			

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
CA 2491310 A1 20040122 CA 2003-2491310 20030715 <--
AU 2003247869 A1 20040202 AU 2003-247869 20030715 <--
US 20040175378 A1 20040909 US 2003-620850 20030715 <--
EP 1537146 A2 20050608 EP 2003-764600 20030715 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
CN 1668644 A 20050914 CN 2003-816751 20030715 <--
JP 2005537267 T 20051208 JP 2004-521771 20030715 <--
BR 2003012692 A 20070626 BR 2003-12692 20030715 <--
ZA 2005000363 A 20070425 ZA 2005-363 20050113 <--
MX 2005000652 A 20050819 MX 2005-652 20050114 <--
IN 2008DN00130 A 20080620 IN 2008-DN130 20080104 <--
PRIORITY APPLN. INFO.: US 2002-396263P P 20020715 <--
WO 2003-US21925 W 20030715
IN 2005-DN416 A3 20050203

AB Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compns. and methods for utilizing these findings in the treatment of cancer and viral infections. Also disclosed are advantageous antibody, immunoconjugate and duramycin-based compns. and combinations that bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases.

L12 ANSWER 7 OF 30 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:41226 CAPLUS
DOCUMENT NUMBER: 140:105321
TITLE: Methods and compositions relating to isoleucine boroproline compounds
INVENTOR(S): Adams, Sharlene; Miller, Glenn T.; Jesson, Michael I.; Jones, Barry
PATENT ASSIGNEE(S): Point Therapeutics, Inc., USA
SOURCE: PCT Int. Appl., 152 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004004658	A2	20040115	WO 2003-US21405	20030709 <--
WO 2004004658	A3	20050804		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2491466	A1	20040115	CA 2003-2491466	20030709 <--
AU 2003265264	A1	20040123	AU 2003-265264	20030709 <--

US 20040077601	A1	20040422	US 2003-616694	20030709 <--
US 20050084490	A1	20050421	US 2003-616409	20030709 <--
EP 1578434	A2	20050928	EP 2003-763380	20030709 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006507352	T	20060302	JP 2004-562634	20030709 <--
CN 1802090	A	20060712	CN 2003-821282	20030709 <--
CN 1826129	A	20060830	CN 2003-821281	20030709 <--
IN 2005KN00151	A	20050916	IN 2005-KN151	20050208 <--
PRIORITY APPLN. INFO.:			US 2002-394856P	P 20020709 <--
			US 2002-414978P	P 20021001 <--
			US 2003-466435P	P 20030428
			WO 2003-US21405	W 20030709

OTHER SOURCE(S): MARPAT 140:105321

AB A method for treating subjects with, inter alia, abnormal cell proliferation or infectious disease using agents of formula (I, AmNHCH(CH(CH3)CH2CH3)COA1R) (where Am and A1 are amino acids and R = organo boronates, organo phosphonates, fluoroalkyl ketones, alphaketos, N-peptidyl-O-(acylhydroxylamines), azapeptides, azetidines, fluoroolefins dipeptide isosteres, peptidyl (α -aminoalkyl) phosphonate esters, aminoacyl pyrrolidine-2-nitriles and 4-cyanothiazolidides) is claimed. Methods for stimulating an immune response using the compds. of the invention are also claimed. Compns. containing Ile-boroPro compds. are also provided as are kits containing the compns. The invention embraces the use of these compds. alone or in combination with other therapeutic agents.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 8 OF 30 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:532527 CAPLUS

DOCUMENT NUMBER: 139:79132

TITLE: Non-nucleosidic inhibitors of reverse transcriptase as antagonists of cell proliferation and inducers of cell differentiation

INVENTOR(S): Spadafora, Corrado; Lavia, Patrizia; Mattei, Elisabetta; Palombini, Guglielmo; Lorenzini, Rodolfo Nello; Granito, Alfredo; Nervi, Clara

PATENT ASSIGNEE(S): Italy

SOURCE: PCT Int. Appl., 41 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 2003055493	A1	20030710	WO 2002-EP14727	20021223 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
IT 2001RM0767	A1	20030624	IT 2001-RM767	20011224 <--
CA 2471543	A1	20030710	CA 2002-2471543	20021223 <--
AU 2002358793	A1	20030715	AU 2002-358793	20021223 <--
AU 2002358793	B2	20080424		

EP 1469858 A1 20041027 EP 2002-793112 20021223 <--
 EP 1469858 B1 20080709
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
 CN 1607953 A 20050420 CN 2002-826053 20021223 <--
 CN 100450487 C 20090114
 JP 2005513147 T 20050512 JP 2003-556070 20021223 <--
 HU 2006000841 A2 20070502 HU 2006-841 20021223 <--
 NZ 534257 A 20080328 NZ 2002-534257 20021223 <--
 AT 400276 T 20080715 AT 2002-793112 20021223 <--
 ES 2309222 T3 20081216 ES 2002-793112 20021223 <--
 MX 2004006205 A 20050725 MX 2004-6205 20040622 <--
 US 20060166970 A1 20060727 US 2005-500270 20050725 <--
 PRIORITY APPLN. INFO.: IT 2001-RM767 A 20011224 <--
 IT 2002-MI1833 A 20020819 <--
 WO 2002-EP14727 W 20021223 <--

AB The invention refers to the use of Reverse Transcriptase (RT) inhibitor
 compds. for the preparation of pharmaceutical compns. to counteract the loss of
 cellular differentiation in tumor and non tumor
 pathologies, said compound being able to bind the hydrophobic pocket on the
 RT subunit p66. Particularly preferred for such uses are the following
 compds.: nevirapine, efavirenz, delavirdine, corresponding salts
 and/or pharmaceutically acceptable derivs. thereof. Growth of Morris
 3924A rat hepatomas were inhibited in rats by treatment with nevirapine or
 efavirenz.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 9 OF 30 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:77550 CAPLUS
 DOCUMENT NUMBER: 138:131149
 TITLE: Treatment of neurological disease
 INVENTOR(S): Hesson, David P.; Pelura, Timothy J.; Frazer, Glen D.
 PATENT ASSIGNEE(S): Integra Lifesciences Corp., USA
 SOURCE: U.S. Pat. Appl. Publ., 14 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20030022879	A1	20030130	US 2002-90442	20020304 <--
US 6689756	B2	20040210		

PRIORITY APPLN. INFO.: US 2001-331359P P 20010302 <--

AB The invention discloses a method of treating an animal infection or
 neoplasm of cerebrospinal tissue characterized by a risk of death.
 The method comprises of : (a) injecting a physiol. acceptable fluid for
 cerebrospinal perfusion into a first catheter into the cerebrospinal
 pathway, which fluid for cerebrospinal perfusion has an therapeutically
 effective amount an agent, the agent selected for effectiveness against the
 infection as identified or diagnosed; (b) withdrawing fluid at a second
 catheter into the cerebrospinal pathway to create a flow and flow pathway
 between the first and second catheters; and (c) maintaining the flow for a
 period of time adapted to perfuse at least 1 CSF volume

L12 ANSWER 10 OF 30 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:695717 CAPLUS
 DOCUMENT NUMBER: 137:210971
 TITLE: Treatment of neurological disease with therapeutic
 agent-containing cerebrospinal perfusion fluid

INVENTOR(S): Hesson, David P.; Pelura, Timothy J.; Frazer, Glenn D.
 PATENT ASSIGNEE(S): Neuron Therapeutics, Inc., USA
 SOURCE: PCT Int. Appl., 38 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002069893	A2	20020912	WO 2002-US6108	20020228 <--
WO 2002069893	A3	20050519		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002242293	A1	20020919	AU 2002-242293	20020228 <--
PRIORITY APPLN. INFO.:			US 2001-798774	A 20010302 <--
			WO 2002-US6108	W 20020228 <--

AB Provided is, among other things, a method of treating in an animal infection or neoplasm of cerebrospinal tissue characterized by a risk of death, the method comprising: (a) injecting a physiologically acceptable fluid for cerebrospinal perfusion into a first catheter into the cerebrospinal pathway, which fluid for cerebrospinal perfusion has a therapeutically effective amount of an agent, the agent selected for effectiveness against the infection as identified or diagnosed; (b) withdrawing fluid at a second catheter into the cerebrospinal pathway to create a flow and flow pathway between the first and second catheters; and (c) maintaining the flow for a period of time adapted to perfuse at least 1 CSF volume

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d L12 20-30 ibib abs

L12 ANSWER 20 OF 30 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2002140576 EMBASE
 TITLE: ISMP adverse drug reactions.
 AUTHOR: Shuster, Joel (correspondence)
 CORPORATE SOURCE: Clinical Pharmacy Practice, Temple University School of Pharmacy, Pennsylvania, PA, United States.
 SOURCE: Hospital Pharmacy, (2002) Vol. 37, No. 4, pp. 358-360+429.
 Refs: 8
 ISSN: 0018-5787 CODEN: HOPHAZ
 COUNTRY: United States
 DOCUMENT TYPE: Journal; (Short Survey)
 FILE SEGMENT: 037 Drug Literature Index
 038 Adverse Reactions Titles
 039 Pharmacy
 LANGUAGE: English
 ENTRY DATE: Entered STN: 2 May 2002
 Last Updated on STN: 2 May 2002

L12 ANSWER 21 OF 30 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights

reserved on STN

ACCESSION NUMBER: 2002083896 EMBASE
TITLE: General health management and long-term care of the renal transplant recipient.
AUTHOR: Cohen, David, Dr. (correspondence); Galbraith, Cynthia
CORPORATE SOURCE: Columbia Presbyterian Hospital, 622 W 168th St, New York, NY 10032, United States. djc5@columbia.edu
SOURCE: American Journal of Kidney Diseases, (2001) Vol. 38, No. 6 SUPPL. 6, pp. S10-S24.
Refs: 47
ISSN: 0272-6386 CODEN: AJKDDP
COUNTRY: United States
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 017 Public Health, Social Medicine and Epidemiology
026 Immunology, Serology and Transplantation
028 Urology and Nephrology
037 Drug Literature Index
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 21 Mar 2002
Last Updated on STN: 21 Mar 2002

AB The steady improvement in short-term success rates in renal transplant patients has translated into better long-term success rates and a large number of patients with long-functioning renal transplants. The necessity for the lifelong administration of immunosuppressive medications to prevent rejection, coupled with the presence in many patients of a variety of other medical problems dating from the period of renal insufficiency prior to the time of renal transplantation, has created a large group of patients with a unique and complex set of long-term medical care needs. Due to the constraints of managed care, considerations of geography, or patient preference, the long-term care of an increasing number of renal transplant recipients has shifted away from the transplant center to the community-based nephrologist or internist. For optimal care to be delivered, it is important that the physician's managing these patients be cognizant of the complex and interacting medical issues involved in their care. Appropriate management can significantly prolong the life of the allograft as well as that of the patient. Guidelines for understanding and managing some of the more important and common general medical problems facing the long-term renal transplant recipient (eg, infectious complications, cardiovascular disease, hypertension, diabetes, hyperlipidemia, malignancy, pregnancy, bone disease, dental care, preventive care) are addressed in this section. .COPYRGT. 2001 by the National Kidney Foundation, Inc.

L12 ANSWER 22 OF 30 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2002057800 EMBASE
TITLE: [Antiretroviral drug resistance testing: Recommendations for interpretation].
L'interpretation des tests genotypiques de resistance aux antiretroviraux.
AUTHOR: Brun-Vezinet, F. (correspondence); Masquelier, B.; Calvez, V.; Chaix, M.-L.; Costagliola, D.; Descamps, D.; Izopet, J.; Ruffault, A.; Tamalet, C.; Bocket, L.; Brodard, V.; Buffet-Janvresse, C.; Chanzy, B.; Cottalorda, J.; Dehee, A.; Deny, P.; Dussaix, E.; Ferchal, F.; Harzic, M.; Ingrand, D.; Kholi, E.; Naudin, C.; Schmuck, A.; Schneider, V.; Si-Mohamed, A.; Huraux, J.-M.
CORPORATE SOURCE: Laboratoire de Virologie, Hopital Bichat-Claude-Bernard, Paris, France.
SOURCE: Virologie, (2001) Vol. 5, No. SPEC. ISS. DEC., pp. S29-S33.
Refs: 8

ISSN: 1267-8694 CODEN: VIROFD
 COUNTRY: France
 DOCUMENT TYPE: Journal; General Review; (Review)
 FILE SEGMENT: 022 Human Genetics
 026 Immunology, Serology and Transplantation
 030 Clinical and Experimental Pharmacology
 037 Drug Literature Index
 004 Microbiology: Bacteriology, Mycology, Parasitology
 and Virology
 LANGUAGE: French
 SUMMARY LANGUAGE: English; French
 ENTRY DATE: Entered STN: 21 Feb 2002
 Last Updated on STN: 21 Feb 2002

AB The use of resistance testing is recommended for monitoring the antiretroviral treatments in human immunodeficiency viruses infected patients. The genotyping assays, which refer to the identification of mutations known to be associated with reduction in antiretroviral drug susceptibility, are more widely used than phenotyping as they are simpler, faster and less expensive. Interpreting genotype results has the objective of predicting the virological response to each antiretroviral from a profile of mutations. The Resistance Group of the ANRS built up an algorithm for interpretation of genotype results with updates twice a year. To develop algorithms is a lengthy and difficult process with several steps. The most relevant algorithms are those based on correlation studies between the mutations present at baseline and the virological response in treated patients. At the international level several groups are comparing the performances of available algorithms on pooled data from therapeutic or resistance trials. Besides the algorithms which can be considered as a tool, the clinical and virological concertation should always be applied for optimizing the choice of the salvage regimen after considering treatment history and other non-resistance associated factors.

L12 ANSWER 23 OF 30 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2001437635 EMBASE
 TITLE: Odyssey toward a healthier world.
 AUTHOR: Hunter, P.A. (correspondence)
 CORPORATE SOURCE: Burnthouse, Burnthouse Lane, Cowfold, Sussex RH13 8DH, United Kingdom.
 SOURCE: Drug News and Perspectives, (2001) Vol. 14, No. 7, pp. 440-447.
 ISSN: 0214-0934 CODEN: DNPEED
 COUNTRY: Spain
 DOCUMENT TYPE: Journal; Conference Article; (Conference paper)
 FILE SEGMENT: 037 Drug Literature Index
 004 Microbiology: Bacteriology, Mycology, Parasitology
 and Virology
 LANGUAGE: English
 SUMMARY LANGUAGE: English
 ENTRY DATE: Entered STN: 3 Jan 2002
 Last Updated on STN: 3 Jan 2002

AB The 22nd International Congress of Chemotherapy was held in Amsterdam, the Netherlands, July 1-4, 2001. The congress attracted participants from around the world and covered a broad spectrum of work on microbial infections and cancer, their treatment by antiinfective drugs and their prevention by vaccination. A theme of the congress was "Compassion and Science", and this was picked up in a fascinating albeit slightly controversial symposium on "Health, Human Rights and Infection". There were several well-attended plenary lectures on topical subjects, including prions and variant Creutzfeldt-Jakob disease and on a possible link between autism and infection. .COPYRGT. 2001 Prous Science. All

rights reserved.

L12 ANSWER 24 OF 30 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2001264203 EMBASE
TITLE: DuPont sells its pharmaceutical operations to Bristol-Myers Squibb.
SOURCE: Manufacturing Chemist, (2001) Vol. 72, No. 7, pp. 5.
ISSN: 0262-4230 CODEN: MCHMDI
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; Note
FILE SEGMENT: 016 Cancer
025 Hematology
032 Psychiatry
033 Orthopedic Surgery
037 Drug Literature Index
LANGUAGE: English
ENTRY DATE: Entered STN: 16 Aug 2001
Last Updated on STN: 16 Aug 2001

L12 ANSWER 25 OF 30 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2001197270 EMBASE
TITLE: 38th Annual Meeting of the SENFC (Spanish Society of Clinical Neurophysiology), Barcelona, Spain, December 14-16, 2000.
AUTHOR: Ferrandiz, M. (correspondence)
CORPORATE SOURCE: Hospital Universitario Josep Trueta, Neurofisiologia Clinica, Avda Franca, s/n, 17007 Gerona, Spain.
SOURCE: Clinical Neurophysiology, (2001) Vol. 112, No. 6, pp. 1128-1138.
ISSN: 1388-2457 CODEN: CNEUFU
PUBLISHER IDENT.: S 1388-2457(01)00539-9
COUNTRY: Ireland
DOCUMENT TYPE: Journal; Conference Article; (Conference paper)
FILE SEGMENT: 027 Biophysics, Bioengineering and Medical Instrumentation
037 Drug Literature Index
038 Adverse Reactions Titles
050 Epilepsy Abstracts
008 Neurology and Neurosurgery
LANGUAGE: English
ENTRY DATE: Entered STN: 14 Jun 2001
Last Updated on STN: 14 Jun 2001

L12 ANSWER 26 OF 30 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2000137200 EMBASE
TITLE: From antivirals to hair loss: Drug review of 1999.
AUTHOR: Hopkins, S.
SOURCE: Manufacturing Chemist, (2000) Vol. 71, No. 4, pp. 12-14.
Refs: 0
ISSN: 0262-4230 CODEN: MCHMDI
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; Note
FILE SEGMENT: 030 Clinical and Experimental Pharmacology
037 Drug Literature Index
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 4 May 2000
Last Updated on STN: 4 May 2000

AB The past year has seen a plethora of compounds come onto market to treat a

myriad of conditions, and they are reviewed here.

L12 ANSWER 27 OF 30 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2000078346 EMBASE
TITLE: US drug and biologic approvals in 1998.
AUTHOR: Spilker, B.; FitzSimmons, S., Dr. (correspondence); Horan, M.
CORPORATE SOURCE: 1100 15(th) Street NW, Washington, DC 20005, United States.
sfitzsim@phrma.org
SOURCE: Drug Development Research, (1999) Vol. 48, No. 4, pp. 139-153.
ISSN: 0272-4391 CODEN: DDREDK
COUNTRY: United States
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 036 Health Policy, Economics and Management
037 Drug Literature Index
039 Pharmacy
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 9 Mar 2000
Last Updated on STN: 9 Mar 2000

AB The Prescription Drug User Fee Act of 1992 enhanced review resources for the Food and Drug Administration (FDA). The past 3 years have seen an unprecedented approval of 122 new drugs and 28 new biologics. Information is provided on the 39 new products approved by the FDA in 1998. (C) 1999 Wiley- Liss, Inc.

L12 ANSWER 28 OF 30 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2000045053 EMBASE
TITLE: New drug update: Etanercept and amprenavir.
AUTHOR: Hussar, D.A., Dr. (correspondence)
CORPORATE SOURCE: Philadelphia College of Pharmacy, Univ. of Sciences in Philadelphia, Philadelphia, PA, United States.
SOURCE: American Druggist, (1999) Vol. 216, No. 12, pp. 52-55.
ISSN: 0190-5279 CODEN: AMDRAG
COUNTRY: United States
DOCUMENT TYPE: Journal; General Review; (Review)
FILE SEGMENT: 030 Clinical and Experimental Pharmacology
031 Arthritis and Rheumatism
037 Drug Literature Index
038 Adverse Reactions Titles
004 Microbiology: Bacteriology, Mycology, Parasitology and Virology
LANGUAGE: English
ENTRY DATE: Entered STN: 10 Feb 2000
Last Updated on STN: 10 Feb 2000

L12 ANSWER 29 OF 30 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2000014482 EMBASE
TITLE: [New drugs in 1999].
Neue arzneimittel 1999.
AUTHOR: Hellwig, B.
SOURCE: Deutsche Apotheker Zeitung, (23 Dec 1999) Vol. 139, No. 51-52 SUPPL., pp. 9-16.
ISSN: 0011-9857 CODEN: DAZE2
COUNTRY: Germany
DOCUMENT TYPE: Journal; (Short Survey)
FILE SEGMENT: 030 Clinical and Experimental Pharmacology
037 Drug Literature Index

LANGUAGE: German
ENTRY DATE: Entered STN: 20 Jan 2000
Last Updated on STN: 20 Jan 2000

L12 ANSWER 30 OF 30 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 1996367259 EMBASE
TITLE: Current Antiviral Agents FactFile. 2nd Edition: Part II - Human immunodeficiency viruses.
AUTHOR: Kinchington, D.; Minshull, C.; Drummond, C.
SOURCE: International Antiviral News, (1996) Vol. 4, No. 7, pp. 132-144.
ISSN: 0965-2310 CODEN: IANWEL
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; General Review; (Review)
FILE SEGMENT: 030 Clinical and Experimental Pharmacology
037 Drug Literature Index
004 Microbiology: Bacteriology, Mycology, Parasitology and Virology
LANGUAGE: English
ENTRY DATE: Entered STN: 9 Jan 1997
Last Updated on STN: 9 Jan 1997

=> s kaposi's sarcoma
MISMATCHED QUOTE 'KAPOSI'S'
Quotation marks (or apostrophes) must be used in pairs, one before and one after the expression you are setting off or masking.

=> s kaposi sarcoma
L13 1017 KAPOSI SARCOMA

=> s L9 and L13
L14 0 L9 AND L13

=> s L9 and sarcoma
L15 16 L9 AND SARCOMA

=> s osteosarcoma
L16 56606 OSTEOSARCOMA

=> s L9 and L16
L17 2 L9 AND L16

=> d 1-2 L17 ibib abs

L17 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2003:610188 CAPLUS
DOCUMENT NUMBER: 139:143905
TITLE: Rapid phenotypic cell-based HIV drug susceptibility assay
INVENTOR(S): McSharry, James J.
PATENT ASSIGNEE(S): Albany Medical College, USA
SOURCE: PCT Int. Appl., 23 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------


```

-----
WO 2003063777      A2      20030807      WO 2003-US2163      20030124 <--
WO 2003063777      A3      20040219
W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
    CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
    GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
    LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
    PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
    UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW:  GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
    KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
    FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF,
    BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
AU 2003210646      A1      20030902      AU 2003-210646      20030124 <--
US 20030181375      A1      20030925      US 2003-350459      20030124 <--
EP 1549773          A2      20050706      EP 2003-734988      20030124 <--
R:   AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
    IE, SI, FI, CY, TR, BG, CZ, EE, HU, SK
PRIORITY APPLN. INFO.:      US 2002-351789P      P 20020125 <--
                                WO 2003-US2163      W 20030124

```

AB The invention provides rapid phenotypic drug susceptibility assays that detect drug resistance in HIV clin. isolates irresp. of the genes containing mutations that lead to drug resistance. The invention provides assays for determining HIV infection and the degree thereof, for determining the efficacy of

candidate HIV inhibitors; and for clin. monitoring the progress of HIV therapies. In one embodiment, methods of the invention feature infecting a cell line expressing CD4, CXCR4, and CCR5 receptors on the cell surface, and a marker gene product, with HIV in the presence of a putative HIV inhibitor, wherein the marker gene product expression increases in response to the cell line infection with HIV; and dynamically counting the number of said cells, e.g., by flow cytometry, expressing the marker gene product and comparing the number of cells expressing the marker gene product to a control value to determine whether the putative HIV inhibitor is an inhibitor of HIV.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:532527 CAPLUS

DOCUMENT NUMBER: 139:79132

TITLE: Non-nucleosidic inhibitors of reverse transcriptase as antagonists of cell proliferation and inducers of cell differentiation

INVENTOR(S): Spadafora, Corrado; Lavia, Patrizia; Mattei, Elisabetta; Palombini, Guglielmo; Lorenzini, Rodolfo Nello; Granito, Alfredo; Nervi, Clara

PATENT ASSIGNEE(S): Italy

SOURCE: PCT Int. Appl., 41 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

```

PATENT NO.      KIND      DATE      APPLICATION NO.      DATE
-----
WO 2003055493      A1      20030710      WO 2002-EP14727      20021223 <--
W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
    CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
    GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
    LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,

```

PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA,
 UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
 FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ,
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

IT 2001RM0767	A1	20030624	IT 2001-RM767	20011224 <--
CA 2471543	A1	20030710	CA 2002-2471543	20021223 <--
AU 2002358793	A1	20030715	AU 2002-358793	20021223 <--
AU 2002358793	B2	20080424		
EP 1469858	A1	20041027	EP 2002-793112	20021223 <--
EP 1469858	B1	20080709		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK

CN 1607953	A	20050420	CN 2002-826053	20021223 <--
CN 100450487	C	20090114		
JP 2005513147	T	20050512	JP 2003-556070	20021223 <--
HU 2006000841	A2	20070502	HU 2006-841	20021223 <--
NZ 534257	A	20080328	NZ 2002-534257	20021223 <--
AT 400276	T	20080715	AT 2002-793112	20021223 <--
ES 2309222	T3	20081216	ES 2002-793112	20021223 <--
MX 2004006205	A	20050725	MX 2004-6205	20040622 <--
US 20060166970	A1	20060727	US 2005-500270	20050725 <--

PRIORITY APPLN. INFO.:

IT 2001-RM767	A	20011224 <--
IT 2002-MI1833	A	20020819 <--
WO 2002-EP14727	W	20021223 <--

AB The invention refers to the use of Reverse Transcriptase (RT) inhibitor compds. for the preparation of pharmaceutical compns. to counteract the loss of cellular differentiation in tumor and non tumor pathologies, said compound being able to bind the hydrophobic pocket on the RT subunit p66. Particularly preferred for such uses are the following compds.: nevirapine, efavirenz, delavirdine, corresponding salts and/or pharmaceutically acceptable derivs. thereof. Growth of Morris 3924A rat hepatomas were inhibited in rats by treatment with nevirapine or efavirenz.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s L15 NOT L12
 L18 12 L15 NOT L12

=> d 1-12 L18 ibib abs

L18 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:534173 CAPLUS

DOCUMENT NUMBER: 141:89016

TITLE: Preparation of
 benzimidazolylazabicyclooctylethylpiperidines as Ccr5
 antagonists for the treatment of HIV infection

INVENTOR(S): Kazmierski, Wieslaw Mieczyslaw; Aquino, Christopher
 Joseph; Bifulco, Neil; Boros, Eric Eugene; Chauder,
 Brian Andrew; Chong, Pek Yoke; Duan, Maosheng; Deanda,
 Felix, Jr.; Koble, Cecilia Suarez; Mclean, Ed
 Williams; Peckham, Jennifer Poole; Perkins, Angilique
 C.; Thompson, James Benjamin; Vanderwall, Dana

PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA; et al.; et al.

SOURCE: PCT Int. Appl., 859 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004054974	A2	20040701	WO 2003-US39644	20031212 <--
WO 2004054974	A3	20040902		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2509711	A1	20040701	CA 2003-2509711	20031212 <--
AU 2003300902	A1	20040709	AU 2003-300902	20031212 <--
EP 1569646	A2	20050907	EP 2003-813419	20031212 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
BR 2003017230	A	20051025	BR 2003-17230	20031212 <--
CN 1744899	A	20060308	CN 2003-80109628	20031212 <--
JP 2006511554	T	20060406	JP 2004-560838	20031212 <--
NO 2005002739	A	20050819	NO 2005-2739	20050607 <--
US 20060229336	A1	20061012	US 2005-538144	20050609 <--
MX 2005006354	A	20050826	MX 2005-6354	20050613 <--
IN 2005KN01328	A	20060630	IN 2005-KN1328	20050711 <--
ZA 2005005600	A	20060927	ZA 2005-5600	20050712 <--
PRIORITY APPLN. INFO.:			US 2002-433634P	P 20021213 <--
			WO 2003-US39644	W 20031212
OTHER SOURCE(S):	MARPAT 141:89016			
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Compds. I [R1 = (optionally substituted) alkyl, aryl, heteroaryl, carbocyclyl; R2 = H, (optionally substituted) alkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, aralkyl, heteroarylalkyl, heteroarylcycloalkyl, aralkylcarbonyl, heteroarylsulfinyl; R3 = H, halo, cyano, trifluoromethyl, (optionally substituted) amino, acylamino, alkyl; X = C1-5 alkylene, optionally substituted with oxo or thioxo groups or halogen atoms, and optionally containing 1-3 oxygen, nitrogen, sulfur, or phosphorus atoms; Y = carbonyl, thiocarbonyl, 1,2-dioxoethylene, oxyalkylcarbonyl, sulfinyl, sulfonyl, oxycyanoimino, (optionally substituted) aminocarbonyl, carbonylamino, aminothiocarbonyl, oxyiminomethyl, thioiminomethyl, amino(cyanoimino)methyl, (cyanoimino)methyl, amino(acylimino)methyl, amino(sulfonylimino)methyl, amino(sulfinylimino)methyl, amino(alkoxyimino)methyl, amino(imino)methyl, (cyanoimino)methoxy, iminomethoxy, (cyanoimino)methanethiyl, alkylcarbonyloxy; A = saturated, partially saturated, or aromatic monocyclic ring

with 5-6 atoms or a bicyclic ring with 8-10 members containing 0-5 nitrogen, oxygen, and/or sulfur atoms] such as II are prepared I are prepared as Ccr5 antagonists for the treatment of viral infections, (particularly HIV infection), related syndromes such as AIDS-related complex (ARC), progressive generalized lymphadenopathy, Kaposi's sarcoma, and neurol. conditions, and other diseases such as multiple sclerosis, rheumatoid arthritis, Crohn's disease, and immune-mediated disorders. The

invention compds. have pIC50 values of ≥ 5 in assays for Ccr5 antagonism. Piperidineacetaldehyde III is prepared in four steps from 4-phenyl-4-piperidinecarbonitrile by protection of the piperidine with Boc anhydride, reduction of the nitrile with diisobutylaluminum hydride, Wittig olefination with methoxymethylphosphonium chloride, and hydrolysis of the enol ether with catalytic p-toluenesulfonic acid monohydrate. The hydrochloride of endo-(benzimidazolyl)azabicyclooctane IV is prepared in five steps from tert-Bu endo-3-oxo-8-azabicyclo[3.2.1]octane-8-carboxylate; reductive amination with benzylamine, reductive cleavage of the benzyl group by palladium-mediated hydrogenation, a nucleophilic aryl substitution reaction with 1-fluoro-2-nitrobenzene, reduction of the nitro group by hydrogenation over palladium on carbon, and treatment with tri-Et orthoacetate followed by treatment with hydrochloric acid in ethanol. Coupling of III and IV by reductive amination with sodium triacetoxyborohydride, cleavage of the Boc group with hydrochloric acid in dioxane, and acylation with pivaloyl chloride and triethylamine yields II.

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:452961 CAPLUS

DOCUMENT NUMBER: 141:21840

TITLE: Human protein FLJ21908/SHIVA (soluble HIV apoptotic) secreted by HIV-1-infected monocytes, and methods for diagnosing and treating AIDS dementia

INVENTOR(S): Sperber, Kirk; Gelman, Irwin H.

PATENT ASSIGNEE(S): USA

SOURCE: PCT Int. Appl., 164 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004045519	A2	20040603	WO 2003-US36382	20031113 <--
WO 2004045519	A3	20050818		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003290876	A1	20040615	AU 2003-290876	20031113 <--
US 20040197770	A1	20041007	US 2003-712671	20031113 <--
EP 1572104	A2	20050914	EP 2003-783461	20031113 <--
EP 1572104	A3	20051005		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			

PRIORITY APPLN. INFO.: US 2002-426103P P 20021114 <--
WO 2003-US36382 W 20031113

AB The present invention generally relates to the treatment or inhibition of diseases associated with HIV-1 infection. In particular, the present invention provides methods and compns. for decreasing, inhibiting, or otherwise abrogating neuronal cell apoptosis that leads to HIV-1 associated dementia (HAD). The inventors described a soluble 6000-Da peptide secreted by an HIV-1-infected human macrophages, which induces apoptosis in the

neuronal cells, as well as T cells and B cell. The inventors identified this factor as the cDNA clone FL14676485 encoding the human protein, FLJ21908 [now referred to as SHIVA (soluble HIV apoptotic)]. The FLJ21908/SHIVA protein induces apoptosis through activation of caspase-9 and caspase-3. The SHIVA protein can be detected in brain and lymph tissue from HIV-1-infected patients who have AIDS dementia, but not in the neuronal tissue of patients with non-HIV associated dementia. The compns. of the present invention may be used systemically for the treatment of HIV to abrogate neuronal, T and B-cell apoptosis. The compns. of the present invention also may be used to ameliorate inflammatory disorders by inducing cell death in such disorders.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:610188 CAPLUS

DOCUMENT NUMBER: 139:143905

TITLE: Rapid phenotypic cell-based HIV drug susceptibility assay

INVENTOR(S): McSharry, James J.

PATENT ASSIGNEE(S): Albany Medical College, USA

SOURCE: PCT Int. Appl., 23 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003063777	A2	20030807	WO 2003-US2163	20030124 <--
WO 2003063777	A3	20040219		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003210646	A1	20030902	AU 2003-210646	20030124 <--
US 20030181375	A1	20030925	US 2003-350459	20030124 <--
EP 1549773	A2	20050706	EP 2003-734988	20030124 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, CY, TR, BG, CZ, EE, HU, SK			

PRIORITY APPLN. INFO.: US 2002-351789P P 20020125 <--
WO 2003-US2163 W 20030124

AB The invention provides rapid phenotypic drug susceptibility assays that detect drug resistance in HIV clin. isolates irresp. of the genes containing mutations that lead to drug resistance. The invention provides assays for determining HIV infection and the degree thereof, for determining the efficacy of candidate HIV inhibitors; and for clin. monitoring the progress of HIV therapies. In one embodiment, methods of the invention feature infecting a cell line expressing CD4, CXCR4, and CCR5 receptors on the cell surface, and a marker gene product, with HIV in the presence of a putative HIV inhibitor, wherein the marker gene product expression increases in response to the cell line infection with HIV; and dynamically counting the number of said cells, e.g., by flow cytometry, expressing the marker gene product and comparing the number of cells expressing the marker gene product

to a control value to determine whether the putative HIV inhibitor is an inhibitor of HIV.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:927617 CAPLUS

DOCUMENT NUMBER: 138:19530

TITLE: Nucleic acid treatment of diseases or conditions related to levels of Ras, HER2 and HIV

INVENTOR(S): McSwiggen, James

PATENT ASSIGNEE(S): Ribozyme Pharmaceuticals, Incorporated, USA

SOURCE: PCT Int. Appl., 185 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 260

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2002097114	A2	20021205	WO 2002-US16840	20020529 <--
WO 2002097114	A3	20030508		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 9851819	A	19980611	AU 1998-51819	19980112 <--
AU 729657	B2	20010208		
AU 9939188	A	19990916	AU 1999-39188	19990713 <--
AU 769175	B2	20040115	AU 2000-56616	20000911 <--
AU 2002305729	A1	20021209	AU 2002-305729	20020529 <--
EP 1390472	A2	20040225	EP 2002-734572	20020529 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
US 20030153521	A1	20030814	US 2002-238700	20020910 <--
WO 2003070912	A2	20030828	WO 2003-US5045	20030220 <--
WO 2003070912	A3	20041111		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003219818	A1	20030909	AU 2003-219818	20030220 <--
EP 1501853	A2	20050202	EP 2003-716093	20030220 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2005517437	T	20050616	JP 2003-569805	20030220 <--
US 20050080031	A1	20050414	US 2003-724270	20031126 <--
US 20050176024	A1	20050811	US 2004-923354	20040820 <--
US 20050288242	A1	20051229	US 2004-923476	20040820 <--

AU 2006203062	A1	20060810	AU 2006-203062	20060713
AU 2006203062	B2	20090312		
AU 2006203725	A1	20060914	AU 2006-203725	20060825
AU 2006228026	A1	20061102	AU 2006-228026	20061011
US 20090099119	A1	20090416	US 2008-192869	20080815 <--
PRIORITY APPLN. INFO.:			US 2001-294140P	P 20010529 <--
			US 2001-296249P	P 20010606 <--
			US 2001-318471P	P 20010910 <--
			AU 1995-26422	A3 19950518 <--
			US 1996-623891	A 19960325 <--
			AU 1996-76662	A3 19961025 <--
			US 2001-292217P	P 20010518 <--
			US 2001-306883P	P 20010720 <--
			US 2001-916466	A 20010725 <--
			US 2001-311865P	P 20010813 <--
			US 2002-358580P	P 20020220 <--
			US 2002-362016P	P 20020306 <--
			US 2002-363124P	P 20020311 <--
			WO 2002-US15876	A2 20020520 <--
			US 2002-157580	A2 20020529 <--
			WO 2002-US16840	W 20020529 <--
			US 2002-163552	A1 20020606 <--
			US 2002-386782P	P 20020606 <--
			US 2002-393924P	P 20020703 <--
			US 2002-406784P	P 20020829 <--
			US 2002-408378P	P 20020905 <--
			US 2002-409293P	P 20020909 <--
			US 2002-238700	A2 20020910 <--
			US 2002-251117	A1 20020919 <--
			US 2002-277494	A1 20021021 <--
			US 2003-440129P	P 20030115
			AU 2003-216323	A3 20030220
			AU 2003-219817	A3 20030220
			AU 2003-221258	A3 20030220
			WO 2003-US5028	A2 20030220
			WO 2003-US5045	W 20030220
			WO 2003-US5346	A2 20030220
			US 2003-417012	B2 20030416
			US 2003-422704	B2 20030424
			US 2003-427160	A2 20030430
			US 2003-444853	A2 20030523
			US 2003-652791	A2 20030829
			US 2003-693059	A2 20031023
			US 2003-720448	A2 20031124
			US 2003-724270	A2 20031126
			US 2003-727780	A2 20031203
			US 2004-757803	A2 20040114
			US 2004-543480P	P 20040210
			US 2004-780447	A2 20040213
			US 2004-826966	A2 20040416
			WO 2004-US13456	A2 20040430
			WO 2004-US16390	A2 20040524
			US 2004-923476	B1 20040820

AB The present invention relates to nucleic acid mols., including enzymic nucleic acid mols., such as DNazymes (e.g. DNA enzymes, catalytic DNA), siRNA, aptamers, and antisense that modulate the expression of Ras genes such as K-Ras, H-Ras, and/or N-Ras, HIV genes such as HIV-1, and HER2 (c-erbB2) gene. The sequence of human HER2 or Ras genes were screened for accessible sites using a computer-folding algorithm. Regions of the RNA that do not form secondary folding structure and contain potential enzymic nucleic acid mol. and/or antisense binding/cleavage sites are identified. The sequences of c-Ki-ras, c-Ha-ras, HER2, and HIV RNA binding/cleavage

sites are provided, as are the sequences of designed enzymic nucleic acid mols., e.g., hammerhead ribozymes, DNazymes, inozymes, zinzymes, and Amberzymes. [This abstract record is one of two records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

L18 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:521462 CAPLUS
DOCUMENT NUMBER: 137:88442
TITLE: Incensole and furanogermacrene and compounds in treatment for inhibiting neoplastic lesions and microorganisms
INVENTOR(S): Shanahan-Pendergast, Elisabeth
PATENT ASSIGNEE(S): Ire.
SOURCE: PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002053138	A2	20020711	WO 2002-IE1	20020102 <--
WO 2002053138	A3	20020919		
W:	AE, AG, AT, AU, BB, BG, CA, CH, CN, CO, CU, CZ, LU, LV, MA, MD, UA, UG, US, VN, YU, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, AT, BE, CH, CY, DE, ES, FI, ML, MR, NE, SN, TD, TG			
AU 2002219472	A1	20020716	AU 2002-219472	20020102 <--
EP 1351678	A2	20031015	EP 2002-727007	20020102 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
US 20040092583	A1	20040513	US 2004-250535	20040102 <--
PRIORITY APPLN. INFO.:			IE 2001-2	A 20010102 <--
			WO 2002-IE1	W 20020102 <--

OTHER SOURCE(S): MARPAT 137:88442

AB The invention discloses the use of incensole and/or furanogermacrene, derivs. metabolites and precursors thereof in the treatment of neoplasia, particularly resistant neoplasia and immunodysregulatory disorders. These compds. can be administered alone or in combination with conventional chemotherapeutic, antiviral, antiparasite agents, radiation and/or surgery. Incensole and furanogermacrene and their mixture showed antitumor activity against various human carcinomas and melanomas and antimicrobial activity against Staphylococcus aureus and Enterococcus faecalis.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2000:628160 CAPLUS
DOCUMENT NUMBER: 133:232870
TITLE: Inhibitors of serine protease activity, and methods and compositions for treatment of viral infections and other conditions
INVENTOR(S): Shapiro, Leland
PATENT ASSIGNEE(S): The Trustees of University Technology Corp., USA
SOURCE: PCT Int. Appl., 87 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2000052034	A2	20000908	WO 2000-US5558	20000303 <--
WO 2000052034	A3	20010111		
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 2000037191	A	20000921	AU 2000-37191	20000303 <--
US 6849605	B1	20050201	US 2000-518098	20000303 <--
US 20060040867	A1	20060223	US 2005-44224	20050128 <--
US 20080051330	A1	20080228	US 2006-404041	20060414 <--
US 20080261868	A1	20081023	US 2008-51373	20080319 <--
PRIORITY APPLN. INFO.:			US 1999-123167P	P 19990305 <--
			US 1999-137795P	P 19990603 <--
			US 1999-153942P	P 19990915 <--
			US 2000-518076	A1 20000303 <--
			US 2000-518081	A1 20000303 <--
			US 2000-518098	A1 20000303 <--
			WO 2000-US5558	W 20000303 <--

OTHER SOURCE(S): MARPAT 133:232870

AB A method of treating and preventing viral infection is provided. In particular, a method of blocking viral infection facilitated by a serine proteolytic activity is disclosed, which consists of administering to a subject suffering or about to suffer from viral infection a therapeutically effective amount of a compound having a serine protease inhibitory or serpin activity. Among compds. are α 1-antitrypsin (AAT), peptide derivs. from the carboxyterminal end of AAT, and man-made, synthetic compds. mimicking the action of such compds. The preferred viral infections include retroviral infection such as human immunodeficiency virus (HIV) infection. A method for treating other pathol. conditions mediated by a serine protease is also disclosed.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 7 OF 12 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2008224767 EMBASE
 TITLE: The changing face of HIV.
 AUTHOR: Smith, N.P. (correspondence); Pozniak, A.L.
 CORPORATE SOURCE: Kobler Clinic, St. Stephen's Centre, Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, United Kingdom.
 SOURCE: Imaging, (2002) Vol. 14, No. 1, pp. 1-7.
 Refs: 31
 ISSN: 0965-6812 CODEN: IAGIEC
 COUNTRY: United Kingdom
 DOCUMENT TYPE: Journal; Article
 FILE SEGMENT: 017 Public Health, Social Medicine and Epidemiology
 026 Immunology, Serology and Transplantation
 030 Clinical and Experimental Pharmacology
 037 Drug Literature Index
 038 Adverse Reactions Titles
 004 Microbiology: Bacteriology, Mycology, Parasitology and Virology
 LANGUAGE: English
 SUMMARY LANGUAGE: English

ENTRY DATE: Entered STN: 21 May 2008

Last Updated on STN: 21 May 2008

AB • Approximately 40 million people are living with HIV/AIDS worldwide.
• 15 000 new infections are estimated to occur each day. • In the West there is little evidence that the number of new HIV infections in at-risk groups is in decline. • A combination of antibiotic prophylaxis and HAART has had a revolutionary impact upon the management of HIV disease in the West. • There has been no reduction in the incidence of AIDS-related tumours. • Drug toxicity is a major concern. • The best hope for controlling HIV disease is with an effective vaccine, an area of intense research. • 85% of HIV infected persons do not have access to effective therapy. .COPYRG. 2002 The British Institute of Radiology.

L18 ANSWER 8 OF 12 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2002391453 EMBASE

TITLE: Patients with HIV infection and fever: A diagnostic approach.

AUTHOR: Florence, E.; Bottieau, E.; Lynen, L.; Colebunders, R.
(correspondence)

CORPORATE SOURCE: Instituut voor Tropische Geneeskunde, Nationalestraat 155,
B - 2000 Antwerpen, Belgium. bcoleb@itg.be

SOURCE: Acta Clinica Belgica, (Jul 2002) Vol. 57, No. 4, pp.
184-190.

Refs: 59

ISSN: 0001-5512 CODEN: ACCBAT

COUNTRY: Belgium

DOCUMENT TYPE: Journal; Article

FILE SEGMENT: 026 Immunology, Serology and Transplantation

037 Drug Literature Index

038 Adverse Reactions Titles

004 Microbiology: Bacteriology, Mycology, Parasitology
and Virology

006 Internal Medicine

LANGUAGE: English

SUMMARY LANGUAGE: English; French

ENTRY DATE: Entered STN: 21 Nov 2002

Last Updated on STN: 21 Nov 2002

AB Fever is a common sign among patients with HIV infection and frequently leads to a medical consultation. It is generally caused by infections. The type of infection depends on the stage of the disease. Opportunistic infections occur only in the presence of severe immunodeficiency. A systematic approach will identify most causes of fever. Since the incidence of opportunistic infections has dramatically decreased with the use of highly active antiretroviral treatments, other causes of fever including immune restoration disease, neoplasm and drug-fever should be considered.

L18 ANSWER 9 OF 12 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2002267346 EMBASE

TITLE: HIV infection and the cardiovascular system.

AUTHOR: Barbaro, Giuseppe (correspondence); Klatt, Edward C.

CORPORATE SOURCE: Viale Anicio Gallo 63, 00174 Rome, Italy. g.barbaro@tin.it

SOURCE: AIDS Reviews, (2002) Vol. 4, No. 2, pp. 93-103.

Refs: 76

ISSN: 1139-6121 CODEN: ADRV6

COUNTRY: Spain

DOCUMENT TYPE: Journal; General Review; (Review)

FILE SEGMENT: 005 General Pathology and Pathological Anatomy

004 Microbiology: Bacteriology, Mycology, Parasitology

and Virology
 038 Adverse Reactions Titles
 037 Drug Literature Index
 036 Health Policy, Economics and Management
 030 Clinical and Experimental Pharmacology
 026 Immunology, Serology and Transplantation
 018 Cardiovascular Diseases and Cardiovascular Surgery
 016 Cancer

LANGUAGE: English

SUMMARY LANGUAGE: English

ENTRY DATE: Entered STN: 8 Aug 2002

Last Updated on STN: 8 Aug 2002

AB Better treatment and supportive care are prolonging the lives of patients with HIV, which is resulting in a higher prevalence of long-term effects of HIV. Autopsy and echocardiography studies support frequent involvement of the heart in advanced stages of HIV infection. The most common cardiac manifestations of HIV are dilated cardiomyopathy, myocarditis, pulmonary hypertension, pericardial effusion, endocarditis, HIV-associated malignant neoplasms, and drug-related cardiotoxicity. Highly active antiretroviral therapy (HAART) has prolonged many patients' lives, but many cardiac sequelae of HIV are not affected by HAART and continue to develop even with treatment. In addition, HAART itself may be associated with an increase in peripheral artery and coronary artery diseases. This review focuses on the most recent knowledge about HIV-associated cardiovascular disease. Careful cardiovascular evaluation in the course of HIV disease can identify cardiac complications early enough to treat. In addition, the study of HIV-related cardiovascular disease may shed light on the mechanisms of non-HIV-related cardiovascular disease.

L18 ANSWER 10 OF 12 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2002217350 EMBASE

TITLE: Pulmonary manifestations of HIV/AIDS in the tropics.

AUTHOR: Slotar, Dylan, Dr. (correspondence)

CORPORATE SOURCE: Department of Internal Medicine, University of Southern California, Keck School of Medicine, 2020 Zonal Avenue, Los Angeles, CA 90033, United States. dslotar@hotmail.com

AUTHOR: Escalante, Patricio

CORPORATE SOURCE: Division of Pulmonary and Critical Care Medicine, University of Southern California Keck School of Medicine, 1200 North State Street, GNH 1900, Los Angeles, CA 90033, United States.

AUTHOR: Jones, Brenda E

CORPORATE SOURCE: Division of Infectious Diseases, University of Southern California Keck School of Medicine, 1200 North State Street, GNH 6442, Los Angeles, CA 90033, United States.

SOURCE: Clinics in Chest Medicine, (2002) Vol. 23, No. 2, pp. 355-367.

Refs: 103

ISSN: 0272-5231 CODEN: CCHMDA

PUBLISHER IDENT.: S 0272-5231(01)00003-X

COUNTRY: United States

DOCUMENT TYPE: Journal; General Review; (Review)

FILE SEGMENT: 015 Chest Diseases, Thoracic Surgery and Tuberculosis
 017 Public Health, Social Medicine and Epidemiology
 037 Drug Literature Index
 006 Internal Medicine

LANGUAGE: English

SUMMARY LANGUAGE: English

ENTRY DATE: Entered STN: 8 Jul 2002

Last Updated on STN: 8 Jul 2002

AB The most significant pulmonary opportunistic infections in the tropics are

TB and pneumococcal pneumonia. Guidelines for the diagnosis and management of these and other pulmonary manifestations of HIV are discussed. Ultimately, unless concerted efforts are made to treat underlying HIV infection in regions most devastated by AIDS, the impact of these diseases will continue to grow.

L18 ANSWER 11 OF 12 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2002033960 EMBASE
TITLE: Plasmablastic lymphoma: An HIV-associated entity with primary oral manifestations.
AUTHOR: Flaitz, C.M. (correspondence)
CORPORATE SOURCE: Department of Stomatology, University of Texas-Houston Health Science Center, Dental Branch, 6516 John Freeman Avenue, Houston, TX 77030, United States. cmflaitz@mail.uth.db.edu
AUTHOR: Nichols, C.M.
CORPORATE SOURCE: Dental Clinic, Bering Community Service Foundation, Houston, TX, United States.
AUTHOR: Walling, D.M.
CORPORATE SOURCE: Department of Internal Medicine, Division of Infectious Disease, University of Texas Medical Branch at Galveston, Galveston, TX, United States.
AUTHOR: Hicks, M.J.
CORPORATE SOURCE: Department of Pathology, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, United States.
AUTHOR: Flaitz, C.M. (correspondence)
CORPORATE SOURCE: Department of Stomatology, Univ. Texas-Houston Hlth. Sci. Ctr., Dental Branch, 6516 John Freeman Avenue, Houston, TX 77030, United States. cmflaitz@mail.uth.db.edu
SOURCE: Oral Oncology, (2002) Vol. 38, No. 1, pp. 96-102.
Refs: 30
ISSN: 1368-8375 CODEN: EJCCER
PUBLISHER IDENT.: S 1368-8375(01)00018-5
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 011 Otorhinolaryngology
016 Cancer
026 Immunology, Serology and Transplantation
037 Drug Literature Index
004 Microbiology: Bacteriology, Mycology, Parasitology and Virology
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 7 Feb 2002
Last Updated on STN: 7 Feb 2002

AB Plasmablastic lymphoma is a relatively new entity that is considered to be a diffuse large B-cell lymphoma with an unique immunophenotype and a predilection for the oral cavity. We present a 50 year-old HIV-positive, bisexual, white male with a CD4 count 300/mm(3) and a viral HIV-RNA polymerase chain reaction (PCR) load of 237 copies/ml, who developed a painful, purple-red mass in the edentulous area of the maxillary right first molar. Erythematous gingival enlargements of the interdental papillae were seen in three of the dental quadrants. In addition, the patient was being managed with antiretroviral therapy and liposomal doxorubicin for recurrent cutaneous Kaposi's sarcoma (KS). Although oral KS was suspected, the gingival lesions were biopsied because they were refractory to chemotherapy and a lymphoma could not be excluded. Histopathologic examination revealed a lymphoid malignant neoplasm, consistent with a plasmablastic lymphoma. Immunoreactivity with vs38c, CD79a, kappa light chain, and IgG was readily identified in tumor cells; while only focal cells expressed CD20 and LCA (CD45RB). CD56, CD3,

lambda light chain, and EMA were non-reactive. EBV was detected in the tumor by Southern hybridization, PCR amplification, in situ hybridization for EBER-1 DNA, and immunohistochemistry for latent membrane protein-1. The same tumor was negative for HHV-8 by PCR. Recognition of plasmablastic lymphoma is important, because it represents an HIV-associated malignancy that predominately involves the oral cavity, may mimic KS and has a poor prognosis. .COPYRGHT. 2002 Elsevier Science Ltd. All rights reserved.

L18 ANSWER 12 OF 12 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2000376000 EMBASE
 TITLE: Highly active antiretroviral therapy does not protect against Kaposi's sarcoma in HIV-infected individuals [6].
 AUTHOR: Zala, C. (correspondence); Ochoa, C.; Krolewiecki, A.; Patterson, P.; Cahn, P.; Crawford, R.I.; Montaner, J.S.G.
 CORPORATE SOURCE: Fundacion Huesped, Buenos Aires, Argentina.
 SOURCE: AIDS, (2000) Vol. 14, No. 14, pp. 2217-2218.
 Refs: 13
 ISSN: 0269-9370 CODEN: AIDSET
 COUNTRY: United Kingdom
 DOCUMENT TYPE: Journal; Letter
 FILE SEGMENT: 016 Cancer
 037 Drug Literature Index
 004 Microbiology: Bacteriology, Mycology, Parasitology and Virology
 LANGUAGE: English
 ENTRY DATE: Entered STN: 16 Nov 2000
 Last Updated on STN: 16 Nov 2000

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	277.19	291.12
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-17.22	-17.22

STN INTERNATIONAL LOGOFF AT 12:25:34 ON 12 JUN 2009